載入中
NASDAQHealthcareBiotechnology
最新資料
US$1.845
−US$0.125 · -6.35%
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
收盤時
US$1.845
−US$0.125 · -6.35%
盤後
US$1.83
−US$0.015 · -0.81%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
日內區間
目前US$1.845
52週區間
目前US$1.845
盤中時間採用ET。市場資料可能有所延遲。
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
日內區間
目前US$1.845
52週區間
目前US$1.845
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | 26.05萬 USD | 12.34萬 USD | 310.06萬 USD |
| 銷貨成本 | — | 2.63萬 USD | 1361.83萬 USD | 6723 USD | 1135.91萬 USD |
| 毛利 | — | −2.63萬 USD | −1335.78萬 USD | 11.67萬 USD | −825.85萬 USD |
| 研究與開發 | 2979.31萬 USD | 1721.05萬 USD | 1361.83萬 USD | 1203.5萬 USD | 1135.91萬 USD |
| 銷售、一般及管理費用 | 2355.51萬 USD | 1137.85萬 USD | 673.19萬 USD | 621.03萬 USD | — |
| 營業費用 | 5197.43萬 USD | 2856.28萬 USD | 673.19萬 USD | 1824.53萬 USD | 650.76萬 USD |
| 利息收入 | 371.51萬 USD | 106.92萬 USD | 106.09萬 USD | 7.45萬 USD | 1.99萬 USD |
| 利息支出 | — | — | — | 7.45萬 USD | 1.99萬 USD |
| 折舊和攤銷 | 6.05萬 USD | 2.63萬 USD | 17.74萬 USD | 6723 USD | 1476.61萬 USD |
| 營業利益 | −5197.43萬 USD | −2858.91萬 USD | −2008.98萬 USD | −1812.86萬 USD | −1476.61萬 USD |
| 淨利 | −4825.92萬 USD | −2751.99萬 USD | −1902.89萬 USD | −1805.42萬 USD | −1478.61萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$6.50
上漲空間 252.30%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2023年6月30日 | 1:6 | — | — |
已生效 2023年6月30日
1:6
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI869.52萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM690.37萬0.01%787.4億 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF232.5萬0.00%954億 USD0.05%US$233.52-0.63%
Vanguard Russell 2000 ETFVTWO160.83萬0.01%180億 USD0.06%US$112.27-0.35%
iShares Micro-Cap ETFIWC89.88萬0.07%13.17億 USD0.60%US$181.66-0.73%
ALPS Medical Breakthroughs ETFSBIO34.65萬0.18%1.91億 USD0.50%US$53.85-2.16%
Vanguard Russell 2000 Value ETFVTWV26.02萬0.02%14億 USD0.06%US$185.97+0.08%
Avantis U.S. Small Cap Equity ETFAVSC24.83萬0.01%30.82億 USD0.25%US$69.97-0.01%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCALPS Medical Breakthroughs ETFSBIOVanguard Russell 2000 Value ETFVTWVAvantis U.S. Small Cap Equity ETFAVSCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
